Tuesday, October 20, 2026
Monday, October 12, 2026
WHEN BREAST CANCER SPREADS IN MEN
Metastatic Male Breast Cancer and the Cost of Invisibility
By: the UNCOVERED (MBCGA) Editorial Team
Breast cancer in men is uncommon. Metastatic breast cancer in men is even less frequently discussed. Yet rarity does not diminish the seriousness of the disease, the complexity of its treatment or the experiences of the men and families living with it.The American Cancer Society estimates that approximately 2,670 American men will be diagnosed with invasive breast cancer in 2026, while approximately 530 will die from it. A man’s lifetime risk is about 1 in 755. Although male breast cancer represents fewer than 1% of breast cancer diagnoses in the United States, these numbers expose a consequential reality: hundreds of men continue to die each year from a disease that many people do not realize men can develop.
What Metastatic Disease Means
Metastatic breast cancer—also called stage IV or distant breast cancer—occurs when cancer cells spread beyond the breast and nearby lymph nodes to other parts of the body. Common metastatic sites include the bones, liver, lungs and brain. A man may have metastatic disease when first diagnosed, or an earlier-stage cancer may return years after apparently successful treatment.
Once breast cancer becomes metastatic, treatment generally shifts from eliminating the disease to controlling it for as long as possible. The objectives include slowing progression, reducing tumor burden, relieving symptoms, preserving organ function and maintaining quality of life. Metastatic breast cancer is not currently considered curable, but it is treatable. Some men live for years as therapies are adjusted in response to tumor biology, disease progression and treatment tolerance.
Recent American Cancer Society data, based on men diagnosed between 2015 and 2021, indicate a five-year relative survival rate of approximately 97% for localized male breast cancer and 86% for regional disease. When the cancer is distant or metastatic at diagnosis, that figure falls to approximately 31%. These percentages describe populations, not individual destinies. A man’s outcome may be influenced by tumor subtype, sites of metastasis, genetic alterations, age, general health, available treatments and response to therapy.
Why Men Are Diagnosed Later
The problem frequently begins with invisibility. Men are not routinely screened for breast cancer, and neither patients nor healthcare professionals always recognize the warning signs promptly. A painless lump, nipple retraction, nipple discharge, skin change or swelling beneath the arm may be dismissed as an infection, injury or benign condition.
Because men generally have less breast tissue, a tumor may also reach the nipple, skin or chest-wall structures comparatively early. At least eight out of ten male breast cancers are invasive ductal carcinomas. Delayed recognition gives a potentially treatable localized cancer more time to advance.
An analysis highlighted by the National Cancer Institute found that 5.8% of men, compared with 3.8% of women, had stage IV breast cancer at diagnosis. The same research found higher mortality among men across all disease stages, even after adjusting for clinical characteristics, treatment, age, race, comorbidities and access to care.
"Men diagnosed with breast cancer experienced a 19% higher adjusted risk of death compared with women, according to a major study published in JAMA Oncology. This disparity was observed across disease stages, underscoring the importance of earlier detection, equitable treatment, and male-specific research." (3)
Treatment Built From Incomplete Evidence
Most male breast cancers are hormone-receptor positive, making endocrine therapy central to treatment. Depending on the tumor, a man may also receive chemotherapy, HER2-targeted therapy, immunotherapy or newer targeted agents. Molecular and germline genetic testing can identify characteristics—including inherited BRCA variants—that may influence treatment and inform relatives about their own cancer risks.
However, men have historically been underrepresented or excluded from breast cancer clinical trials. Consequently, many treatment recommendations have been extrapolated from research conducted predominantly among women. This approach provides essential therapeutic options, but it leaves important questions concerning male biology, drug response, dosing, adverse effects and quality of life insufficiently answered.
The Human Burden Behind the Mortality Data
Metastatic male breast cancer creates burdens extending beyond tumor control. Men may experience pain, fatigue, reduced mobility, sexual-health changes, body-image concerns, anxiety and financial pressure. Some encounter disbelief when they disclose their diagnosis. Others enter treatment environments in which educational materials, support groups and visual messaging appear designed exclusively for women.
Racial disparities deepen the concern. The National Cancer Institute reports that Black men are generally diagnosed at a later stage and are more likely to die from breast cancer than White men. This makes metastatic male breast cancer not only a clinical issue, but also an awareness, access and health-equity challenge.
Male breast cancer may be rare, but the men living—and dying—with metastatic disease must not remain invisible. The goal is not simply to acknowledge that men can develop breast cancer. It is to ensure that every man receives timely diagnosis, scientifically informed treatment, meaningful support and a genuine opportunity to live longer and better.
References
1) American Cancer Society. (2025, October 15). Key statistics for breast cancer in men. https://www.cancer.org/cancer/types/breast-cancer-in-men/about/key-statistics.html www.cancer.org
2) American Cancer Society. (2025, October 15). Survival rates for breast cancer in men. https://www.cancer.org/cancer/types/breast-cancer-in-men/detection-diagnosis-staging/survival-rates.html www.cancer.org
3) Scientific reference: Wang, F., et al. (2019). Overall mortality after diagnosis of breast cancer in men vs women. JAMA Oncology, 5(11), 1589–1596. https://doi.org/10.1001/jamaoncol.2019.2803
4) Chen, W., Huang, Y., Lewis, G. D., Szeja, S. S., Hatch, S. S., Farach, A., Miltenburg, D., Butler, E. B., Chang, J. C., & Teh, B. S. (2018). Treatment outcomes and prognostic factors in male patients with stage IV breast cancer: A population-based study. Clinical Breast Cancer, 18(1), e97–e105. https://doi.org/10.1016/j.clbc.2017.07.005 Scholars @ UT Health San Antonio
5) Hassett, M. J., Somerfield, M. R., Baker, E. R., Cardoso, F., Kansal, K. J., Kwait, D. C., Plichta, J. K., Ricker, C., Roshal, A., Ruddy, K. J., Suman, V. J., & Giordano, S. H. (2020). Management of male breast cancer: ASCO guideline. Journal of Clinical Oncology, 38(16), 1849–1863. https://doi.org/10.1200/JCO.19.03120 PubMed
6) Leone, J. P., Freedman, R. A., Leone, J., Tolaney, S. M., Vallejo, C. T., Leone, B. A., Winer, E. P., Lin, N. U., & Hassett, M. J. (2023). Survival in male breast cancer over the past 3 decades. JNCI: Journal of the National Cancer Institute, 115(4), 421–428. https://doi.org/10.1093/jnci/djac241 The Male Breast Cancer Global Alliance
7) National Cancer Institute. (2025, February 27). Breast cancer in men. https://www.cancer.gov/types/breast/male-breast-cancer www.cancer.gov
8) Sirieix, J., Fraisse, J., Mathoulin-Pelissier, S., Leheurteur, M., Vanlemmens, L., Jouannaud, C., Diéras, V., Lévy, C., Ung, M., Mouret-Reynier, M.-A., Petit, T., Coudert, B., Brain, E., Pistilli, B., Ferrero, J.-M., Goncalves, A., Uwer, L., Patsouris, A., Tredan, O., … Frénel, J.-S. (2020). Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME). Therapeutic Advances in Medical Oncology, 12, 1–13. https://doi.org/10.1177/1758835920980548 journals.sagepub.com
9) Zheng, G., & Leone, J. P. (2022). Male breast cancer: An updated review of epidemiology, clinicopathology, and treatment. Journal of Oncology, 2022, Article 1734049. https://doi.org/10.1155/2022/1734049 PubMed
Legal statements:
© 2026 Male Breast Cancer Institute. All Rights Reserved. Produced by the Male Breast Cancer Institute. Sponsored by the Male Breast Cancer Global Alliance. www.MBCGlobalInstitute.org All original text, graphic designs, educational materials, and campaign content are protected by applicable copyright laws. Unauthorized reproduction, distribution, modification, or commercial use is prohibited without prior written permission, except as permitted by law. This publication is provided for general educational and public awareness purposes only and does not constitute medical advice, diagnosis, treatment, or professional healthcare recommendations.
Metastatic breast cancer is a complex medical condition. Its presentation, progression, treatment, and prognosis vary among individuals. Readers should consult qualified healthcare professionals regarding symptoms, screening, diagnosis, treatment options, and individual medical decisions. Medical images, anatomical illustrations, and patient representations are provided for educational or illustrative purposes and may not depict actual patients, clinical findings, or individual disease progression.
The Male Breast Cancer Institute and Male Breast Cancer Global Alliance make no guarantees regarding medical outcomes. Information presented reflects available scientific knowledge and should not replace individualized medical evaluation or care.
Monday, October 5, 2026
DRAFT ONLY: Do Not Share ("The Hidden Disparities behind an Overlooked Disease"
Male Breast Cancer and Men of Color: The Hidden Disparities behind an Overlooked Disease
An examination of
racial disparities, international patterns, social barriers and the urgent need
for more inclusive cancer detection.
Male breast cancer is an overlooked disease. For men of color, it
represents an even greater challenge, exposing disparities in healthcare,
cultural awareness, early detection, research participation and survival. While
breast cancer awareness has achieved remarkable progress, much of the public
conversation continues to exclude men, leaving important populations
inadequately represented in education, research and advocacy.
The
statistics reveal a troubling reality. Black men in the United States
experience disproportionately higher rates of male breast cancer than White
men, while international research identifies significant disease burdens in
parts of sub-Saharan Africa. Yet these numbers raise questions that extend
beyond genetics and biology. How many men remain undiagnosed? How many delay
seeking medical attention because breast cancer is perceived as a woman's
disease? How accurately do existing cancer registries represent underserved
populations?
This article
examines the available evidence, explores potential explanations for racial and
geographic disparities, and identifies opportunities to improve awareness,
screening, diagnostic access and research.
Most
importantly, it challenges us to reconsider how we communicate about male
breast cancer. Greater visibility, inclusive research and culturally responsive
education are essential to ensuring that every man, regardless of race,
ethnicity or nationality, has an opportunity for earlier detection and improved
survival.
THE
DISPARITIES WE CAN NO LONGER IGNORE
Male breast
cancer is already an underrecognized disease. For men of color, the challenges
can be compounded by racial disparities in cancer outcomes, unequal access to
healthcare, cultural misconceptions and a shortage of research addressing
different populations. Although breast cancer in men represents approximately
1% of all breast cancer diagnoses in the United States, its relatively low
incidence has contributed to a dangerous misconception: that all men face
essentially the same risks.
They do not.
Research has identified meaningful differences in incidence, age at diagnosis,
tumor characteristics and survival among racial and ethnic populations.
Understanding these differences requires examining not only biology but also
the social circumstances that determine who receives information, who seeks
medical attention and who obtains timely treatment.
The
American picture: What the numbers reveal
The American
Cancer Society estimates that approximately 2,670 American men will be
diagnosed with invasive breast cancer in 2026, while approximately 530 will die
from the disease. The average lifetime risk is approximately one in 755 men. However, these national estimates conceal
substantial disparities.
Source: American Cancer Society, Breast Cancer Facts & Figures 2024–2025.
A separate
American Cancer Society study found that Black men experienced 52% higher
breast cancer incidence than White men. Importantly, the disparity extended
across multiple tumor subtypes, suggesting that the problem cannot be
attributed to one particular form of breast cancer.
International
disparities: Where is the burden greatest?
The international
picture raises equally important questions. A Global Burden of Disease analysis
covering 204 countries and territories estimated 38,827 new male breast cancer
cases and 13,274 deaths worldwide in 2021.
International findings
Worldwide new
cases, 2021: 38,827
Worldwide deaths,
2021: 13,274
Eastern
sub-Saharan Africa: Highest estimated regional age-standardized incidence and
mortality rates.
Uganda: Highest estimated
national incidence and mortality rates in the analysis, at 4.54 and 3.51 per
100,000, respectively.
These are modeled
estimates, not complete national cancer registry counts.
These findings
warrant greater investigation into African populations and men of African
ancestry. However, geography should not be confused with ethnicity. African,
Caribbean, Hispanic, Asian, Indigenous and Middle Eastern populations are
internally diverse, and available evidence does not support assigning a uniform
breast cancer risk to any nationality.
Why
might these differences exist?
Researchers are
investigating several possible explanations, including inherited genetic
susceptibility, hormonal influences, obesity, environmental exposures and
differences in access to healthcare.
BRCA2 mutations
are an established male breast cancer risk factor, but the reasons for the
elevated incidence among Black men remain unresolved. Social and economic
inequalities may also contribute to differences in survival.
An important distinction
is necessary: genetic ancestry, nationality and socially defined race are not
interchangeable. Population-level disparities should generate research
questions rather than assumptions about individual patients.
The
social barriers: Why men remain invisible
Breast cancer
continues to be presented predominantly as a women's disease. For men,
particularly those in communities where masculinity, privacy and cultural
expectations discourage discussion of breast health, acknowledging symptoms may
present additional challenges.
These barriers
may be compounded by limited insurance coverage, mistrust of healthcare
institutions, inadequate culturally appropriate education and the absence of
male representation in breast cancer campaigns. Such explanations require
community-specific research rather than cultural generalizations.
The consequences
deserve attention. National Cancer Institute research indicates that Black men
are more likely than White men to receive a later-stage diagnosis and to die
from breast cancer.
Earlier
detection: A practical response
The solution is
not indiscriminate mammography for every man. It is informed, individualized
assessment and timely investigation of symptoms.
Healthcare
professionals and community advocates should prioritize five actions:
- Educate men
to recognize breast lumps, nipple discharge, nipple inversion, skin
changes and enlarged underarm lymph nodes.
- Encourage
prompt clinical assessment of suspicious changes, followed by diagnostic
mammography, ultrasound and biopsy when appropriate.
- Offer
genetic counseling and appropriate testing to men with breast cancer or
significant inherited risk.
- Discuss
individualized surveillance with men who have pathogenic BRCA variants or
other substantial risk factors.
- Expand
culturally appropriate outreach and improve racial, ethnic and ancestry
data collection in cancer registries.
Routine screening
mammography is not generally recommended for average-risk men. Screening
decisions for higher-risk men should be individualized.
Ultimately,
reducing disparities requires more than identifying which populations
experience greater risk. It demands research participation, culturally informed
education, accessible diagnostic services and public recognition that breast
cancer has no gender or racial boundaries.
Every man
deserves to recognize the warning signs, understand his individual risk and
receive timely care.
Research
references
1.
American
Cancer Society: Key Statistics for Breast Cancer in Men (2026)
2.
American
Cancer Society: Breast Cancer Facts & Figures 2024–2025
3.
Subtype-Specific
Breast Cancer Incidence Rates in Black Versus White Men
4.
Racial
and Ethnic Disparities and Socioeconomic Determinants of Male Breast Cancer
Mortality
5.
Global,
Regional and National Burden of Male Breast Cancer in 204 Countries
6.
National
Cancer Institute: Breast Cancer in Men
7.
National
Cancer Institute: Male Breast Cancer Treatment
8.
National
Cancer Institute: BRCA1 and BRCA2, Genetic Risk and Surveillance
References
The following references cover male breast cancer incidence, racial and
ethnic disparities, international epidemiology, genetics, screening, treatment
outcomes and barriers to care.
1. American Cancer Society. (2024). Breast cancer facts & figures
2024–2025. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/2024/breast-cancer-facts-and-figures-2024.pdf
2. American Cancer Society. (2026). Key statistics for breast cancer in men.
https://www.cancer.org/cancer/types/breast-cancer-in-men/about/key-statistics.html
3. American College of Radiology. (2025). ACR Appropriateness Criteria®:
Male breast cancer screening. https://acsearch.acr.org/docs/3196044/Narrative
4. Crew, K. D., Neugut, A. I., Wang, X., Jacobson, J. S., Grann, V. R.,
Raptis, G., & Hershman, D. L. (2007). Racial disparities in treatment and
survival of male breast cancer. Journal of Clinical Oncology, 25(9), 1089–1098.
https://doi.org/10.1200/JCO.2006.09.1710
5. Freeman, J. Q., Schechter, K., Nguyen, L. C., Omoleye, O. J., & Hara,
J. H. (2026). Racial and ethnic disparities and socioeconomic determinants of
male breast cancer mortality in the United States. Breast Cancer Research and
Treatment, 215, Article 9. https://doi.org/10.1007/s10549-025-07851-y
6. Li, Y., Huang, Y., Huang, H., Wei, T., Zhang, A., Xing, L., Yin, X., Li,
H., Ren, G., & Li, F. (2025). Global, regional, and national burden of male
breast cancer in 204 countries and territories: A systematic analysis from the
Global Burden of Disease Study, 1990–2021. eClinicalMedicine, 80, Article
103027. https://doi.org/10.1016/j.eclinm.2024.103027
7. National Cancer Institute. (n.d.). BRCA gene changes: Cancer risk and
genetic testing fact sheet. https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet
8. National Cancer Institute. (n.d.). Male breast cancer treatment
(PDQ®)–Health professional version. https://www.cancer.gov/types/breast/hp/male-breast-treatment-pdq
9. National Cancer Institute. (n.d.). Male breast cancer treatment
(PDQ®)–Patient version. https://www.cancer.gov/types/breast/patient/male-breast-treatment-pdq
10. National Cancer Institute. (n.d.). Genetics of breast and gynecologic
cancers (PDQ®)–Health professional version. https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq
11. Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022).
Cancer statistics, 2022. CA: A Cancer Journal for Clinicians, 72(1), 7–33. https://doi.org/10.3322/caac.21708
12. Sung, H., DeSantis, C., & Jemal, A. (2020). Subtype-specific breast
cancer incidence rates in Black versus White men in the United States. JNCI Cancer
Spectrum, 4(1), Article pkz091. https://doi.org/10.1093/jncics/pkz091
13. U.S. Cancer Statistics. (n.d.). U.S. cancer statistics data
visualizations. Centers for Disease Control and Prevention. https://www.cdc.gov/cancer/uscs/dataviz/
14. World Health Organization. (2024). Breast cancer. https://www.who.int/news-room/fact-sheets/detail/breast-cancer
15. World Health Organization, International Agency for Research on Cancer.
(2024). Global Cancer Observatory: Cancer today. https://gco.iarc.who.int/today/
MBC GLOBAL ALLIANCE FALL WEBINAR: THE GENETIC BLUEPRINT
Featuring: Dr Kara Maxwell & Harvey Singer
THE
GENE MEN CANNOT AFFORD TO IGNORE
Dr. Kara Maxwell and Male
Breast Cancer Survivor Harvey Singer Bring BRCA, Screening and Family Risk Into
Focus
UNCOVERED
| Male Breast Cancer Global
Special Report | September 22, 2026
PROLOGUE
For decades,
public understanding of BRCA mutations has largely been shaped through the lens
of women, breast cancer and ovarian cancer. That narrative is incomplete. Men
inherit BRCA mutations. Men transmit them to their children. And for some men,
these inherited mutations can significantly alter their risks for breast,
prostate, pancreatic and other cancers.
On September
22, 2026, Dr. Kara Maxwell,
Director of the Men & BRCA Program at the
Together,
physician and survivor delivered a message that deserves greater attention:
understanding inherited cancer risk is not simply about predicting disease. It
can provide an opportunity to screen differently, communicate with family
members, advocate for appropriate care and potentially identify cancer earlier.
BRCA IS NOT JUST A WOMEN’S
HEALTH ISSUE
Dr. Kara
Maxwell approached the subject by first addressing one of its most persistent
misconceptions: BRCA mutations are not “female genes.”
Maxwell
directs the Men & BRCA Program at the
Maxwell began
her September presentation with a primer on genetics, explaining how variants
and mutations in DNA can affect the function of proteins and, in some cases,
increase susceptibility to cancer. She stressed an especially important
concept: genetic medicine is
continually changing.
Testing
performed years ago may not have examined the same number of genes or types of
variants detectable by contemporary technology. For that reason, an individual
who underwent genetic testing years earlier should not necessarily assume that
the subject is permanently closed.
The
implications are particularly important for male breast cancer survivors.
Maxwell
emphasized that men diagnosed with breast cancer should undergo germline
genetic testing regardless of age or family history. She also discussed genetic
evaluation in prostate and pancreatic cancer and explained how family histories
of breast, ovarian, pancreatic and prostate cancers may provide important clues
to inherited cancer susceptibility.
The family
history must include both sides of
the family. A pathogenic BRCA mutation can be inherited from
either the mother or father and transmitted by either men or women.
DR.
KARA MAXWELL
“Many men do
not think that they need to get genetic testing, that the breast cancer gene is
a female gene, it can only be passed through mothers, it only affects women,
and none of those things are true.”
TESTING IS CHANGING—AND
YESTERDAY’S TEST MAY NOT BE ENOUGH
One of the
most consequential portions of Maxwell’s presentation involved the evolution of
genetic testing itself.
BRCA1 and
BRCA2 remain central to hereditary breast cancer discussions, but Maxwell also
addressed genes including PALB2, ATM
and CHEK2. She explained that laboratories and genetic panels
have changed over time and that older tests may not have evaluated all the
genetic alterations detectable today.
This makes
the actual genetic-testing report important. Patients should know what type of
testing they received, which genes were examined and whether subsequent
advances might justify updated testing.
The problem
is not merely theoretical.
Maxwell
discussed research examining thousands of men with cancers including breast,
pancreatic and metastatic prostate cancer. Even among men with breast
cancer—where genetic testing recommendations have existed for years—the testing
rates she presented remained inadequate. Her central conclusion was direct: not
enough men with breast cancer are receiving genetic testing.
That gap
represents more than a missed scientific opportunity. A genetic result can
influence surveillance, treatment, future cancer risk assessment and decisions
affecting an entire biological family.
HARVEY SINGER: WHEN A GENETIC
LESSON BECOMES A FAMILY STORY
Harvey Singer
gave Maxwell’s presentation an extraordinary human dimension.
Singer is a
male breast cancer survivor, BRCA2 mutation carrier and advocate. During the
discussion, he described a family history that seemed almost to illustrate
Maxwell’s presentation in real time.
His younger
sister, a four-time breast cancer survivor, was known to carry the BRCA
mutation. Singer himself was subsequently diagnosed with male breast cancer and
later prostate cancer. His older brother, also BRCA2-positive, developed
pancreatic cancer.
Yet Singer
acknowledged that when he was initially warned that he might carry the
mutation, he reacted much like many other men.
Breast cancer
did not seem like a disease that should concern him.
It did.
Singer
eventually learned that he carried BRCA2. His understanding of cancer risk
changed dramatically. Screening was no longer simply routine healthcare; it
became a personalized surveillance strategy informed by genetics and family
history.
HARVEY
SINGER
“Having an
understanding of carrying a mutation allows you to screen effectively.”
Singer
described learning to monitor his health differently, including breast,
prostate and pancreatic surveillance. He also spoke about another difficult
aspect of hereditary cancer: telling family members.
His two sons
responded differently to the possibility of genetic testing. One wanted to be
tested quickly. The other waited years.
That
hesitation, Singer suggested, is part of the challenge. Some individuals fear
that knowing about a mutation will cause them to live under the shadow of
cancer. Yet his experience demonstrates the alternative interpretation:
knowledge can provide an opportunity to act.
Singer’s
mother also struggled with guilt over having passed the mutation to her
children. Maxwell responded to that concern by emphasizing that inherited
mutations are not anyone’s fault. What matters clinically is recognizing risk
and giving relatives an opportunity to make informed decisions.
SCREENING IS NOT ABOUT
FINDING MORE CANCER. IT IS ABOUT FINDING IT EARLIER.
The
interaction between Maxwell and Singer produced perhaps the most important
message of the program.
Cancer
surveillance should not be understood simply as an effort to “find cancer.” Its
value is the possibility of identifying disease earlier, when treatment choices
and outcomes may be different.
Maxwell noted
that treatments themselves can carry significant physical burdens. Earlier
detection may influence how extensive treatment must become and how profoundly
cancer disrupts a person’s life.
She also
challenged another persistent misconception: men can undergo mammography.
Men have
breast tissue, and mammography can be performed in men. Maxwell discussed the
continuing research surrounding mammographic surveillance in male BRCA carriers
and expressed strong support during the discussion for mammography among male
breast cancer survivors.
The
presentation also addressed a subject rarely included in public discussions of
male breast cancer: reconstruction.
Men
undergoing breast cancer surgery may have options involving scar revision, fat
grafting, implants, tissue reconstruction and nipple reconstruction or
tattooing. Maxwell noted that some male patients were never informed that
reconstructive options existed.
The issue
extends beyond appearance. It speaks to dignity, body image and quality of life
after cancer.
A PROBLEM WITHIN HEALTHCARE
ITSELF
Singer also
directed attention toward the healthcare system.
Throughout
his cancer experience, he said he encountered healthcare professionals who were
surprised that a man could develop breast cancer.
His
observation raises a significant educational concern. Male breast cancer is
rare, but rarity should not translate into invisibility.
Singer argued
that male breast cancer needs greater inclusion in medical education and
primary care. Men themselves may not know to ask about their breasts during
routine examinations, while clinicians may not routinely examine male breast
tissue or discuss hereditary breast cancer risk.
Maxwell
agreed that genetics needs greater integration into primary care, including
stronger family-history assessment and clinicians who are sufficiently familiar
with hereditary cancer syndromes to recognize when genetic evaluation is
appropriate.
That issue
becomes increasingly important as genetic science grows more complex.
WHY DR. MAXWELL’S
PRESENTATION MATTERS
The
importance of Maxwell’s September 22 presentation was not simply the amount of
genetic information presented. Its greater value was the way she connected
genetics to action.
A BRCA result
is not merely a laboratory finding.
It can
influence breast surveillance. It can affect prostate and pancreatic cancer
risk assessment. It may influence certain treatment decisions. It can lead
relatives to genetic counseling. It can change how a family interprets
generations of cancer diagnoses that previously appeared unrelated.
Maxwell’s
presentation also challenged the concept that a negative genetic test
necessarily ends the investigation. Genetic knowledge is still developing. New
cancer-associated genes continue to be studied, variants are reclassified and
testing technology continues to improve. Family history therefore remains
important even when testing has not identified a clearly pathogenic mutation.
Harvey Singer
provided the living counterpart to that science.
His breast
cancer, prostate cancer, BRCA2 status and family history transformed Maxwell’s
discussion from genetic theory into a recognizable human story.
As Maxwell
observed during their exchange, the two had not coordinated Singer’s story to
match her presentation. It simply did.
That may have
been the most powerful lesson of the program.
Genetics is
not abstract when it appears across generations of a family. It becomes a tool
for understanding what happened—and potentially changing what happens next.
PULL QUOTE | DR. KARA MAXWELL
“The
screening gives you the power to find it early.”
Early
detection, Maxwell emphasized, is not simply about identifying disease. It may
change treatment and reduce the impact cancer has on a patient’s life.
PULL QUOTE | HARVEY SINGER
“Knowing
your risks… and knowing how to advocate for yourself with those risks are
imperative.”
Singer’s
experience illustrates how genetic information can transform a survivor from a
passive recipient of care into an informed participant in lifelong
surveillance.
WHAT MEN SHOULD KNOW ABOUT
BRCA
UNCOVERED Educational Brief
BRCA
is not exclusively about women. Men can inherit BRCA1 or BRCA2 mutations and
can pass them to sons or daughters.
Male
breast cancer matters genetically. Men diagnosed with breast cancer should
discuss germline genetic testing with their healthcare team. Maxwell emphasized
during the presentation that male breast cancer itself is an indication for
genetic evaluation.
Look
at both sides of the family. Cancer history on a father’s side is just as
relevant as history on a mother’s side. Breast, ovarian, pancreatic, prostate
and male breast cancers within a family may provide important clues.
Older
genetic testing may warrant another conversation. Genetic panels and
technology have changed substantially. Someone tested years ago should discuss
with a genetics professional whether the original testing remains adequate.
BRCA
can involve more than breast cancer. In men, pathogenic BRCA mutations can
also be associated with increased risks of prostate and pancreatic cancers.
BRCA2 is particularly important in discussions of male cancer risk.
Men
can have mammograms. Male breast tissue can be imaged. The appropriate
screening plan depends upon individual risk, personal cancer history, genetic
status and medical guidance.
Genetic
information affects families. A positive result may have implications for
siblings, children and other biological relatives. Genetic counseling can help
families understand what a result means and whether relatives should consider
testing.
A
negative result does not erase family history. Genetics continues to
evolve. Screening decisions may still be influenced by a significant personal
or family cancer history.
Know
the report—not simply “positive” or “negative.” Patients should
understand which genes were tested, what type of test was performed and whether
a variant of uncertain significance was identified.
Knowledge
creates options. Genetic information can help guide surveillance, conversations
with healthcare professionals, treatment considerations and family
communication.
THE MESSAGE
For men, BRCA
awareness should not create fear. It should create informed vigilance.
As the September
22, 2026 discussion between Dr. Kara Maxwell and Harvey Singer demonstrated,
genetics can connect generations of cancer history—but it can also provide
families with something earlier generations may never have had:
the
opportunity to know, to screen, to advocate and to act.
Educational
reporting based on the September 22, 2026 presentation and discussion featuring
Dr. Kara Maxwell and Harvey Singer. This article is intended for educational
and informational purposes and does not replace individualized medical advice,
genetic counseling, diagnosis or treatment.
Sunday, October 4, 2026
CASES & MORTALITY: TRACKING THE NUMBERS
MALE BREAST CANCER: THE NUMBERS, THE KNOWLEDGE GAP, AND THE NEW REASONS FOR HOPE
Written by: Carmen R. DeWitt / National Cancer Collective
2026 U.S.
estimates reveal the continuing burden of male breast cancer, while advances in
research, growing public awareness, and survivor advocacy offer opportunities
to improve detection, treatment, and survival. A Special Report from the Male
Breast Cancer Global Alliance October 2026 | Male Breast Cancer Awareness Month
The Numbers Tell a Story. But Are We Hearing the Whole Story?
An estimated 2,670 American men will be diagnosed with invasive breast cancer in 2026, and approximately 530 will die from the disease, according to the American Cancer Society (ACS). Although male breast cancer represents fewer than 1% of all U.S. breast cancer diagnoses, these figures underscore a persistent public health challenge: a disease that remains insufficiently recognized among men and frequently receives attention only after diagnosis.
New educational
graphics developed by the Male Breast Cancer Global Alliance (MBCGA), examining
ACS annual estimates from 2008 through 2026, illustrate both the changing
reported burden and the importance of understanding what these statistics
actually measure.
2026 U.S. MALE BREAST CANCER ESTIMATES
2,670 Estimated new cases
530 Estimated deaths
Source: American
Cancer Society, Cancer Facts & Figures 2026.
The historical comparison is revealing. In 2008, ACS projected approximately 1,990 new cases and 450 deaths among American men. By 2023, those annual projections had reached 2,800 new cases and 530 deaths. The 2026 projections represent approximately 34% more new diagnoses than the 2008 estimate.
Importantly, these figures do not establish that the underlying incidence rate has increased by the same percentage. Changes in population size, age distribution, statistical methods, and disease occurrence can all influence annual estimates.
The most recent four-year comparison shows projected new cases fluctuating between 2,670 and 2,800, while estimated annual deaths have remained close to 530.
Behind
the Statistics: Why Counting Matters
Understanding how
cancer statistics are produced is essential to interpreting them responsibly.
However, another challenge exists beyond statistical reporting: ensuring that men recognize symptoms, seek medical evaluation, and receive appropriate diagnoses.
Men may dismiss a breast lump, misunderstand their personal risk, or hesitate to discuss symptoms because breast cancer is commonly perceived as a women's disease. These barriers can contribute to delayed diagnosis and reinforce the need for targeted education.
The National Cancer Institute reports that male breast cancer is often diagnosed at a later stage than female breast cancer. This makes early recognition and timely medical evaluation particularly important.
Giving Men a Voice—and a Place in the Data
Her advocacy highlights an important distinction. Diagnosed cancers are generally reportable to cancer registries; men do not have to publicly disclose their diagnoses to be counted. However, men who delay seeking medical attention may remain undiagnosed, and those who do not participate in research or advocacy may be absent from other valuable sources of information.
"Our challenge is not simply counting the men who receive a diagnosis. It is reaching those who do not recognize the symptoms, those who are reluctant to seek help, and those whose experiences have never been heard. We need better information, greater participation, and a community where every man feels comfortable coming forward."
A second proposed statement emphasizes the opportunity created by growing awareness. "There is tremendous hope in seeing more men willing to share their stories. Every conversation can encourage another man to seek medical attention. Every patient who participates in research helps us better understand this disease. Awareness is how we begin changing the future."
How
Cancer Data Are Actually Collected
The June 2026 federal data release includes cancer diagnoses through 2023. Its quality-controlled registry information covers the entire U.S. population for that diagnosis year. This provides an increasingly comprehensive foundation for understanding cancer incidence, although reporting delays and differences in participation in research remain important considerations.
Research
Is Creating New Reasons for Hope
Perhaps the most
encouraging development is the recognition that male breast cancer deserves
greater representation in clinical research. Historically, men were frequently
excluded from breast cancer treatment trials. The U.S. Food and Drug
Administration has addressed this disparity by recommending that clinical
trials include both men and women unless a scientific justification supports
exclusion.
This represents a meaningful change in research expectations, creating opportunities to generate treatment evidence directly relevant to male patients.
Genetic
counseling and testing also offer opportunities to identify inherited cancer
susceptibility and inform personalized care. Meanwhile, improved understanding
of tumor biology and established breast cancer therapies provides a foundation
for further male-specific investigation.
Early detection remains especially important. According to the National Cancer Institute, five-year relative survival for localized male breast cancer is approximately 95%, compared with 20% for metastatic disease. These figures reinforce the importance of recognizing symptoms and obtaining prompt medical evaluation.
Beyond
Awareness: Building a Stronger Tomorrow
For MBCGA, the
next chapter must extend beyond increasing public recognition. Greater
collaboration among survivors, clinicians, researchers, advocacy organizations,
and healthcare institutions can help address longstanding gaps in education,
clinical participation, and survivorship support.
As more men speak publicly, their experiences can help shape research priorities and encourage others to recognize symptoms and seek care. Their participation can also strengthen patient-centered research and improve understanding of the challenges associated with living beyond diagnosis.
The 2026 estimates remind us that hundreds of American men continue to die from breast cancer each year. But the expansion of research participation, genetic knowledge, and community advocacy provides tangible reasons for hope. The objective is not simply to count more men. It is to reach them earlier, understand their disease more completely, and ultimately save more lives.
References and Further Reading
American Cancer Society. (2026). Cancer facts & figures 2026. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2026-cancer-facts-figures.html
2. American Cancer Society. (2026). Key statistics for breast cancer in men. https://www.cancer.org/cancer/types/breast-cancer-in-men/key-statistics.html
3. American Cancer Society. (n.d.). Cancer facts and statistics. https://www.cancer.org/research/cancer-facts-statistics.html
4. National Cancer Institute. (n.d.). Male breast cancer treatment (PDQ®)–Health professional version. https://www.cancer.gov/types/breast/hp/male-breast-treatment-pdq
5. National Cancer Institute. (n.d.). Cancer stat facts: Male breast cancer. https://seer.cancer.gov/statfacts/html/maleb.html
6. Centers for Disease Control and Prevention. (n.d.). United States cancer statistics. https://www.cdc.gov/united-states-cancer-statistics/
7. Centers for Disease Control and Prevention. (n.d.). U.S. cancer statistics: Incidence data sources. https://www.cdc.gov/united-states-cancer-statistics/technical-notes/incidence-data-sources.html
8. U.S. Food and Drug Administration. (2020). Male breast cancer: Developing drugs for treatment. Guidance for industry. https://www.fda.gov/media/130061/download
9. U.S. Food and Drug Administration. (n.d.). Men with breast cancer need more treatment options and access to genetic counseling. https://www.fda.gov/consumers/consumer-updates/men-breast-cancer-need-more-treatment-options-and-access-genetic-counseling
10. American Cancer Society. (n.d.). Breast cancer survival rates in men. https://www.cancer.org/cancer/types/breast-cancer-in-men/detection-diagnosis-staging/survival-rates.html
11. National Cancer Institute. (n.d.). Breast cancer in men. https://www.cancer.gov/types/breast/male-breast-cancer
© 2026 Male Breast Cancer Global Alliance (MBCGA). All Rights Reserved.
COPYRIGHT, RESEARCH ATTRIBUTION & EDITORIAL DISCLAIMER
This article was prepared by the writers and reporters of UNCOVERED, a publication of the Male Breast Cancer Global Alliance (MBCGA), as part of an academic research, public education, and cancer awareness initiative.
The statistical data, research findings, and scientific information presented in this report were obtained from the publicly available sources identified in the references below. MBCGA acknowledges the original authors, researchers, institutions, and organizations responsible for these publications.
While reasonable efforts have been made to accurately represent the referenced materials, MBCGA does not independently verify, guarantee, warrant, or assume responsibility for the accuracy, completeness, reliability, or continued validity of third-party data, research findings, projections, or conclusions. The inclusion of referenced information does not constitute an endorsement of every finding or interpretation.
This publication is intended exclusively for educational, informational, and awareness purposes. Its contents should not be interpreted as medical advice or as a substitute for professional medical consultation. Opinions and editorial interpretations expressed in this article are those of its contributors and do not necessarily represent the positions of the referenced institutions.
Source attribution: All external research materials and statistical sources are acknowledged in the references accompanying this article.
Subscribe to:
Posts (Atom)
-
Yeah, you read that right. Breast cancer doesn't care if you have pecs instead of breasts. It's time to kill the myth: male breast c... -
MEDICAL DIAGNOSTIC TRAILBLAZER IS THE NEXT MUSCLE IN MALE BREAST CANCER ADVOCACY 5-24-2025 / New York , NY — In a groundbreaking move th... -
A Physician’s Mission to Expose, Detect, and Defend Against an Overlooked Crisis By Robert L. Bard, MD - Diagnostic Imaging Specialist | Can...